Abstract
Diagnostic accuracy of anti-DNase I antibodies measurement in a differentiation between SLE and other autoimmune rheumatic diseases was evaluated. The share of anti-DNase I and actin in the DNase I activity decrease in SLE was established. Serum samples were obtained from 54 patients with verified SLE, 52 control patients with other autoimmune rheumatic diseases, and 44 healthy persons. Anti-DNase I concentrations were measured by ELISA. Free and actin inhibited DNase I activities were evaluated in the fresh serum samples. The appraisal of antibodies and actin effects on DNase I activity was made using multiple regression. Anti-DNase I antibodies were positive in 35 SLE and 8 control patients, without significant difference between the mean antibody concentrations. Sensitivity of this test was 64.81 %, and specificity—84.62 %. Mean free DNase I activity in SLE was somewhat lower than in the control group as a result of augmented frequency of extremely low enzyme activities. On the contrary, after the exclusion of the latter cases we have revealed elevated mean free DNase I activity in the other SLE patients comparing to the similar control subgroup. Unlike the controls, low serum DNase I activity in SLE arose not only from actin and antibody action, but also, in half of the cases, from unidentified factor, related to active SLE. The accuracy of the anti-DNase I antibodies measurement is approximate to the present reference standard of SLE diagnostics. We first demonstrated that neither antibodies nor actin caused DNase I activity decrease in SLE.
Similar content being viewed by others
References
Heidenreich U, Mayer G, Herold M, Klotz W, Stempfl Al-Jazrawi K, Lhotta K (2009) Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Lupus 18:1276–1280. doi:10.1177/0961203309345753
Bizzaro N, Villalta D, Giavarina D, Tozzoli R (2012) Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 12:97–106. doi:10.1016/j.autrev.2012.07.002
Fritzler MJ (2011) The antinuclear antibody test: last or lasting gasp? Arthritis Rheumatol 63:19–22. doi:10.1002/art.30078
Yeh TM, Chang HC, Liang CC et al (2003) Deoxyribonuclease-inhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 10:544–551
Tew MB, Johnson RW, Reveille JD et al (2001) A molecular analysis of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheumatol 44:2446–2447
Sallai K, Nagy E, Derfalvy B et al (2005) Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus assay. Clin Diagn Lab Immunol 12:56–59. doi:10.1128/CDLI.12.1.56-59.2005
Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M (2009) DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 18:418–423. doi:10.1177/0961203308098189
Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313–314. doi:10.1038/91070
Bodaño A, González A, Balada E, Ordi J, Carreira P, Gómez-Reino JJ, Conde C (2007) Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. Ann Rheum Dis 66:560–561. doi:10.1136/ard.2006.067140
Belguith-Maalej S, Hadj-Kacem H, Kaddour N, Bahloul Z, Ayadi H (2009) DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects. Rheumatol Int 30:69–74. doi:10.1007/s00296-009-0917-4
AlFadhli S, Ghanem AA (2014) Influence of HumDN1 VNTR polymorphism on DNASE1 expression in systemic lupus erythematosus and rheumatoid arthritis. Immunol Investig 43:411–423. doi:10.3109/08820139.2013.864666
Feng XB, Shen N, Qian J et al (2004) Single nucleotide polymorphisms of deoxyribonuclease I and their expression in Chinese systemic lupus erythematosus patients. Chin Med J 117:1670–1676
De Meester I, De Smedt SC (1997) Deoxyribonuclease I. In: Lauwers A, Sharpe S (eds) Pharmaceutical enzymes. Marcel Dekker, New York, pp 285–304
Napirei M, Gultekin A, Kloeckl T et al (2006) Systemic lupus erythematosus: deoxyribonuclease 1 in necrotic chromatin disposal. Int J Biochem Cell Biol 38:297–306. doi:10.1016/j.biocel.2005.10.023
Seredkina N, van der Vlag J, Berden J, Mortensen E, Rekvig OP (2013) Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med 19:161–169. doi:10.2119/molmed.2013.00010
Fenton K (2015) The effect of cell death in the initiation of lupus nephritis. Clin Exp Immunol 179:75–84. doi:10.1111/cei.12417
World Medical Association (1997) Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925–926. doi:10.1001/jama.1997.03540350075038
Wallace DJ, Hahn BH (eds) (2013) Dubois’ lupus erythematosus and related syndromes, 8th edn. Elsevier Saunders, Philadelphia
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol 40:1725. doi:10.1002/art.1780400928
Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 62:2569–2581. doi:10.1002/art.27584
American Rheumatism Association (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheumatol 23:581–590
Tanimoto K, Nakano K, Kano S et al (1995) Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22:668–674
Vitali C, Bombardieri S, Moutsopoulos HM et al (1993) Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheumatol 36:340–347. doi:10.1002/art.1780360309
Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheumatol 33:1129–1134. doi:10.1002/art.1780330811
Lightfoot RW Jr, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheumatol 33:1088–1093. doi:10.1002/art.1780330805
Mills JA, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch–Schönlein purpura. Arthritis Rheumatol 33:1114–1121. doi:10.1002/art.1780330809
Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheumatol 33:1122–1128. doi:10.1002/art.1780330810
Petri M, Kim MY, Kalunian KC et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550–2558. doi:10.1056/NEJMoa051135
Shapot VS, Chudinova IA, Krechetova GD (1964) Methods of isolation and activity measurement of the nucleases. In: Orekhovich VN (ed) Modern methods in biochemistry, vol 1. Meditsina, Moscow, pp 267–280 (in Russian)
Kunitz M (1950) Crystalline desoxyribonuclease. I. Isolation and general properties. Spectrophotometric method for the measurement of desoxyribonuclease activity. J Gen Physiol 33:349–362
Macanovic M, Lachmann PJ (1997) Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108:220–226. doi:10.1046/j.1365-2249.1997.3571249.x
Romanov AI, Trofimenko AS, Simakova ES, Alekhina IU (2008) Prospects of activity evaluation of serum DNase I and its inhibitors in immunodiagnostics of lupus erythematosus. Kremlevskaya meditsina Klinicheskii vestnik http://unmc.su/wp-content/uploads/2013/01/Journal-1-2008.pdf. Accessed 15 Jan 2013 (in Russian)
Zborovskaya IA, Trofimenko AS, Gontar IP (2007) Anti-DNase I antibody response in systemic lupus erythematosus: a possible way of the enzyme dysfunction. Nauchno-Prakticheskaya Revmatol 45:64–68. doi:10.14412/1995-4484-2007-3 (in Russian)
Tinazzi E, Puccetti A, Gerli R et al (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol 21:237–243. doi:10.1093/intimm/dxn142
Kavanaugh AF, Solomon DH (2002) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheumatol 47:546–555. doi:10.1002/art.10558
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A. S. Trofimenko, I. P. Gontar, A. B. Zborovsky, and O. V. Paramonova declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Online Resource 1
Distributions of anti-DNase I concentrations in the reference, control, and SLE group. Dotted line marks cutoff point for the positive results. Means and standard errors for entire groups are also indicated (TIFF 89262 kb)
Online Resource 2
Dependence between fDNase concentrations and SELENA–SLEDAI scores in SLE patients. Columns and error bars represent means and 95 % CI, respectively. In subgroups without any dispersion, 95% CI are not shown (TIFF 102461 kb)
Rights and permissions
About this article
Cite this article
Trofimenko, A.S., Gontar, I.P., Zborovsky, A.B. et al. Anti-DNase I antibodies in systemic lupus erythematosus: diagnostic value and share in the enzyme inhibition. Rheumatol Int 36, 521–529 (2016). https://doi.org/10.1007/s00296-016-3437-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-016-3437-z